Podcasts about covid-19 vaccine

What did Dr. Anthony Fauci know privately about COVID vaccines—and what was the American public being told at the same time? On this episode of The Truth with Lisa Boothe, Senator Ron Johnson joins Lisa for an explosive conversation about his ongoing investigation into the government's COVID-19 response and newly obtained communications from Fauci’s government-issued devices. Johnson discusses a private Fauci message that he says raised concerns about vaccination and pregnancy, why he believes the issue goes far beyond the debate over miscarriage statistics, and his argument that Americans were denied information necessary to make fully informed medical decisions. The Wisconsin senator also reveals what investigators are finding as they work through tens of thousands of Fauci text messages, hundreds of voice messages and other government records. Johnson explains why identifying the people behind hundreds of phone numbers has become a critical part of the investigation—and why he says his team is being careful not to release private information unrelated to public policy. Lisa and Sen. Johnson also discuss Fauci’s handling of the COVID pandemic, gain-of-function research, vaccine safety surveillance, the relationship between government health agencies and pharmaceutical companies, and Johnson’s allegations that career bureaucrats are resisting efforts to uncover additional records. Johnson says investigators are now seeking devices and communications associated with other former government health officials as his probe expands—and declares that despite years of pursuing answers about the pandemic, the investigation has “only just begun.” Plus, Johnson explains why he believes America still needs a full COVID reckoning before the next public health crisis.See omnystudio.com/listener for privacy information.

What happens when someone who volunteered for a COVID-19 vaccine clinical trial says the shot changed her life within hours? On this episode of The Tudor Dixon Podcast, Tudor sits down with Brianne Dressen, co-founder of React19 and a participant in the AstraZeneca COVID-19 vaccine clinical trial, to discuss her experience with what she describes as a severe and lasting vaccine injury. Dressen recounts developing neurological symptoms shortly after receiving the shot, including burning and tingling, numbness, difficulty walking, sensitivity to light and sound, vision problems, and cognitive issues. She says some symptoms remain with her nearly six years later. She also describes receiving treatment at the National Institutes of Health, saying the intervention produced a significant improvement but that she has continued to require treatment. Tudor and Dressen discuss informed consent during vaccine trials, the treatment of people reporting adverse events, Anthony Fauci and the NIH, pharmaceutical-company accountability, and Dressen's allegations that officials knew more about certain adverse effects than was publicly acknowledged. Dressen also explains why she believes further federal investigation is necessary. It’s a wide-ranging conversation about one woman's experience, unanswered questions from the COVID era, and the continuing debate over transparency, medical treatment, and accountability. Subscribe to The Tudor Dixon Podcast on iHeartRadio, Apple Podcasts, YouTube, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Was the "I can't breathe" chant tied to masks part of a ritual and are syringes and mRNA vials equivalent to crosses and holy water? Congress has held a hearing of Dr. Anthony Fauci, which is about 10% serious, where he constantly pleads the fifth under legal council because they know his Pardon is worthless. He will be publicly burdened with all the guilt before permanently retiring from public view with his wealth and remanning years of his life. Everyone else involved, including Governors like Andrew Cuomo--who admitted he had no real power after the fact--has their guilt and culpability absolved by the Fauci scapegoat while the very people behind creating this monster now take credit for his public crucifixion in an attempt to gain back what little trust the traumatized public is wiling to part with in exchange for "2 minutes hate." The current White House leadership was behind Operation Warp Speed and subsidizing mRNA specific products while targeting the non-mRNA producers (additionally, he backed these products after it was no longer viable to deny their danger), the  $2.2 Trillion of artificial stimulus under the CARES Act, invocation of the Defense Production Act to manufacture ventilators and #N95 masks, the promotion of alternative treatments like hydroxychloroquine (largely manufactured by Israel's Teva Pharmaceuticals, the same company behind GAHT drugs), and then awarded sociopaths like Jared Kushner and Anthony Fauci a presidential commendation. His administration did nothing to combat the out of control tyrants in sates like New York or California that abused their power, threatened and lied to the public, destroyed businesses, and turned citizens against each other. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below.

In this episode of The Better Life, Dr. Pinkston sits down with Harvard-trained physician, consultant, and author Dr. Michael Myers Jr. to tackle the complex and often controversial topic of vaccines through the lens of sound science and clear data. With deep expertise as a former chief of primary care and pediatrics, Dr. Myers previews his upcoming book, The Vaccine Bible, and unpacks how immunization works as a reliable tool for long-term health and disease prevention. Together, Dr. Pinkston and Dr. Myers address the most common concerns shared by patient communities today, including the safety of combination shots, the reality of preservatives, and the thoroughly debunked links between vaccines and autism. They look closely at the critical role vaccines play in modern longevity—highlighting massive clinical wins like the shingles vaccine’s link to reduced dementia risk, and cancer-preventing tools like the Gardasil and Hepatitis B vaccines. Dr. Myers also breaks down the rapid development and safety of mRNA technology used during the COVID-19 pandemic. Tune in for an honest, evidence-based conversation that bridges the gap between integrative health practices and conventional immunology, empowering you to perform your own objective risk assessment for you and your family. https://www.drmikemyers.com/ See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is undergoing substantial shifts, marked by leadership changes, regulatory updates, scientific breakthroughs, and strategic expansions.A significant development involves BioNTech's CEO Ugur Sahin and CMO Ozlem Tureci departing to establish a new company focused on next-generation mRNA technologies. This move has sparked discussions about BioNTech's future trajectory without its founders' guidance, considering their pivotal role in developing the COVID-19 vaccine. Analysts are concerned about BioNTech's ability to continue innovating and expanding its mRNA platform independently. As they transition roles, BioNTech is steering towards becoming a multiproduct commercial biotech entity, potentially diversifying its pipeline beyond vaccines towards broader therapeutic applications.In regulatory news, Novo Nordisk's U.S. headquarters recently received a warning letter from the FDA following an inspection, highlighting ongoing compliance challenges. This situation underscores the critical importance of maintaining rigorous quality standards in pharmaceutical manufacturing to avoid regulatory setbacks. Meanwhile, Novo Nordisk has partnered with Hims & Hers to distribute GLP-1 drugs Ozempic and Wegovy targeting diabetes management—a move resolving previous legal disputes while emphasizing digital health integrations into traditional pharmaceutical frameworks.On a more positive note, the FDA has approved leucovorin for an ultra-rare subset of cerebral folate deficiency without requiring clinical trials. This decision might suggest a shift towards more flexible regulatory pathways for rare diseases, potentially accelerating treatments for patients with unmet medical needs. The FDA is also working on its fourth revision of draft guidance on biosimilar testing requirements to streamline the approval process for these cost-effective alternatives to biologic drugs, thereby reducing barriers to market entry and fostering competition.In scientific advancements, Vertex Pharmaceuticals reported positive Phase 3 results for povetacicept, a kidney disease treatment poised for expedited FDA approval. This underscores ongoing innovation in addressing chronic conditions with high unmet needs. Vertex is advancing with a rolling biologics license application supported by late-stage data from the RAINIER study, aiming to address unmet medical needs within chronic kidney disease management.Meanwhile, researchers at Emory University are exploring artificial intelligence as a tool to detect heart disease through breast mammogram screenings, potentially revolutionizing cardiovascular risk assessment by integrating AI into routine diagnostics.CSL is investing $1.5 billion in a plasma-based medicine facility near Chicago, marking a strategic expansion aimed at enhancing production capacity for plasma-derived therapies. This move aligns with growing global demand for plasma products and underscores CSL's commitment to scaling operations to meet patient needs.Turning to other industry trends, Breakout Ventures has announced a $114 million fund dedicated to companies integrating artificial intelligence with scientific endeavors. This investment highlights the transformative potential of AI in accelerating drug discovery and optimizing research processes.Political scrutiny over the FDA's handling of rare disease drug approvals is intensifying. Senator Ron Johnson has launched an investigation into recent rejections, signaling potential future changes in how regulatory agencies balance innovation with safety and efficacy standards.The cell and gene therapy sectors are experiencing robust growth prospects. Recent analysis projects that this market will skyrocket to $146 billion by 2032, reflecting increasing investments and advSupport the show

Question six, the House of Parliament Question Time. Winston Peters to Simeon Brown. The mandate for 12 to 17 year olds and the double dose of the vaccine – seek it out, it's a fascinating exchange. Tuesday, Chris Hipkins and Ayesha Verral denied the concerns raised by the Ministry of Health ever reached their desks. Peters presented evidence it did, and even after it did it took a very long time for anything to be done about it. So a couple of issues out of that. Firstly, it is potentially a misleading of the House – a very serious issue. More importantly, a misleading of us. There is little more egregious for a number of New Zealanders out of the Covid experience than the vaccine issue. Sadly, a lot of the noise around it was tin hat material driven by Ouija board thinking, but some of it, not much, but some of it was real. The risks became a lightning rod. All vaccines carry risk, but concerns were raised about rushed development. And then making that risk higher, mandating of that rushed development into the arms of New Zealanders. Also making this complicated is the line between politics and health, politics and expertise. The government has a right to ignore advice – they do it all the time. But can you ignore health advice – an area you are not expert in? Part of what Peters raised, that may well be a longer term issue, is legal. Is there a case to be heard, whereby a government knew of a problem around a vaccine and yet did nothing with that knowledge until later. Meantime any number of young people were exposed to a risk they didn't have to be. Associated with the stance is the broader, but not legal aspect of this. If that is the sort of approach a government can take, then how does that dovetail with the overarching view that governments want vaccine rates in the high 90s – in other words, they want public trust. A lot of the Covid response and report is about interpretation and ideology. This appears much more specific, worrying, and potentially dishonest. Watch this space. See omnystudio.com/listener for privacy information.

Happy Birthday Joyce!! She talks about the disqualification of Trump appointee Alina Habba as N.J Prosecutor, as Alina calls out a several republicans for colluding against her. The Association of Psychological Science finds that sexism is no longer an issue in the workplace. The FBI investigating six lawmakers who made a video to the military telling them to undermine President Trump. Lack of gratitude and writing off others success as privilege, and playing the victim.At least 10 children reportedly died after COVID-19 vaccination, data that was reportedly hidden by the Biden Administration . Specific chapters of the Muslim brotherhood to be designated as terrorist groups. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“The amount of chaos that's been introduced into the federal health policy landscape is unprecedented,” says Michelle Mello, professor at Stanford Law School and the Stanford University School of Medicine.That turmoil, she explains, has left major gaps in expertise, trust, and leadership—and states are rushing to fill the void. In this episode of Stanford Legal, host Pamela S. Karlan talks with Mello about what this moment means for the future of science, public health, research, and the law.Mello describes how the hollowing out of career expertise at the U.S. Department of Health and Human Services has upended vaccine policy and research funding, forcing states into unfamiliar leadership roles. She and Karlan also unpack how shifting scientific guidance during the pandemic eroded public confidence, how politicized grant-making is reshaping the research ecosystem, and state governments' growing role in creating what she calls a “shadow CDC.”Despite the turmoil, Mello points to a few bright spots: state-level experimentation could generate valuable evidence of what works and what does not, and there are reassuring signs from the lower courts, she says, which she believes are capable of separating law from politics.Earlier this year, Mello explored many of these themes in her JAMA Health Forum paper, “The Hard Road Ahead for State Public Health Departments.”Links:Michelle Mello >>> Stanford Law pageJAMA Health Forum paper >>> “The Hard Road Ahead for State Public Health DepartmentsConnect:Episode Transcripts >>> Stanford Legal Podcast WebsiteStanford Legal Podcast >>> LinkedIn PageRich Ford >>>  Twitter/XPam Karlan >>> Stanford Law School PageDiego Zambrano >>> Stanford Law School PageStanford Law School >>> Twitter/XStanford Lawyer Magazine >>> Twitter/X (00:00:00) Health Policy and COVID-19 Vaccines(00:05:10) The Vaccine Rollout Challenges(00:10:25) Public Trust and Recommendations(00:16:40) The Role of the Vaccine Committee(00:23:55) NIH Grant Process Insight(00:29:43) MIT's Stance on NIH Compact Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Elias Sayour, a pediatric hematologist and oncologist, joins Lester Kiewit to discuss research suggesting that Pfizer and Moderna mRNA COVID-19 vaccines can enhance the effectiveness of immunotherapy in some cancer patients. Dr. Sayour explains that when administered within 100 days of starting checkpoint inhibitor treatment, the vaccines “act like a 911 siren,” mobilizing immune cells to better target tumors, with evidence observed across cancers including lung, melanoma, breast, and head and neck cancers. While the findings are retrospective and not yet definitive, Dr. Sayour highlights the potential for future trials and the broader promise of mRNA technology in cancer therapy, universal vaccines, and personalized immune responses. “Even if we run a phase three trial and it doesn’t work, it is my sincere belief that this idea holds merit,” he says. Good Morning Cape Town with Lester Kiewit is a podcast of the CapeTalk breakfast show. This programme is your authentic Cape Town wake-up call. Good Morning Cape Town with Lester Kiewit is informative, enlightening and accessible. The team’s ability to spot & share relevant and unusual stories make the programme inclusive and thought-provoking. Don’t miss the popular World View feature at 7:45am daily. Listen out for #LesterInYourLounge which is an outside broadcast – from the home of a listener in a different part of Cape Town - on the first Wednesday of every month. This show introduces you to interesting Capetonians as well as their favourite communities, habits, local personalities and neighbourhood news. Thank you for listening to a podcast from Good Morning Cape Town with Lester Kiewit. Listen live on Primedia+ weekdays between 06:00 and 09:00 (SA Time) to Good Morning CapeTalk with Lester Kiewit broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/xGkqLbT or find all the catch-up podcasts here https://buff.ly/f9Eeb7i Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. CDC Director Monarez was fired after less than a month due to internal unrest over new COVID-19 vaccine policies. Novo Nordisk is investing over $500 million in RNA obesity treatments. The FDA has approved updated COVID-19 shots from Pfizer, Moderna, and Novavax with restrictions, causing concern among some groups. Prothena's Alzheimer's drug, PRX012, has shown high rates of brain swelling in Phase I testing. Novo Nordisk is collaborating with other companies on cardiometabolic treatments. The pharma industry is facing challenges and changes, with layoffs and restructurings occurring at various companies. Massachusetts has seen a decline in R&D and biomanufacturing jobs in 2024. Various webinars and events are being held to discuss topics such as pharma manufacturing and data accessibility. Job opportunities in the pharmaceutical industry include positions in business analysis, quality engineering, and project engineering.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta Therapeutics experienced a significant drop in shares as the FDA considers requesting a halt to shipments of the Duchenne muscular dystrophy therapy Elevidys. This decision comes after a third patient death linked to the underlying platform. The company's stock plummeted by 37% on Friday afternoon as reports of the potential shipment stop circulated in the media. This news adds to the already turbulent week for Sarepta, which has been facing challenges in its gene therapy and siRNA biotech developments. ## Novartis announced positive results from a phase 3 trial of its drug Cosentyx in treating axial spondyloarthritis. The study showed that patients treated with Cosentyx had significant improvements compared to those on a placebo. These results further solidify Novartis' position in the market for treatments of autoimmune diseases. The company plans to submit the data to regulatory authorities for potential approval of this indication.Novartis revealed encouraging outcomes from a phase 3 trial of its drug Cosentyx for treating axial spondyloarthritis. The study demonstrated that patients who received Cosentyx experienced notable enhancements compared to those who were given a placebo. These findings strengthen Novartis' standing in the autoimmune disease treatment market. The company intends to present the data to regulatory bodies for potential approval of this indication.## AstraZeneca faced setbacks as it announced delays in delivering its COVID-19 vaccine doses to the EU. The company cited production issues as the cause of the holdup, leading to frustration among European officials. This news comes at a time when vaccine distribution is crucial in combating the ongoing pandemic, highlighting the challenges faced by pharmaceutical companies in meeting global demand for vaccines.AstraZeneca encountered obstacles when it disclosed delays in distributing its COVID-19 vaccine doses to the EU. The company attributed production problems as the reason for the delay, causing frustration among European officials. This development occurs during a critical period in vaccine distribution to combat the current pandemic, underscoring the difficulties pharmaceutical companies encounter in meeting worldwide vaccine demands.## Pfizer and BioNTech announced plans to test a third dose of their COVID-19 vaccine to assess its effectiveness against new variants of the virus. The study will involve participants who have already received two doses of the vaccine and will evaluate the immune response generated by a booster shot. This initiative reflects ongoing efforts by pharmaceutical companies to adapt their vaccines to combat emerging strains of the virus.Pfizer and BioNTech unveiled intentions to examine a third dose of their COVID-19 vaccine to determine its efficacy against new virus variants. The research will include individuals who have already been administered two doses of the vaccine and will assess the immune response produced by an additional shot. This undertaking demonstrates continuous endeavors by pharmaceutical firms to modify their vaccines in response to evolving virus mutations.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former FDA official Peter Marks criticized the agency's new risk-based COVID-19 vaccine framework, stating it contradicts the administration's transparency and science standards. The CDC's advisory committee recommended Merck's infant RSV vaccine, and Novavax's approval delay raised concerns about politicization of drug approval processes. Lilly's Verve deal revealed regulatory turmoil following Marks' resignation. Meanwhile, Trump's CDC pick supports vaccine safety, Novartis made a large bet on cardiovascular disease targets, and RFK cut US funding from vaccine alliance Gavi. The biopharma industry is hiring less international talent, and pharma companies face challenges with failed immuno-oncology projects. Evotec is hosting a webinar on preserving quality in the pharmaceutical industry.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: FDA approves new drug for treatment of rare genetic diseaseIn a significant development for the rare disease community, the FDA has approved a new drug for the treatment of a rare genetic disease. The drug, which is the first of its kind, has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition.##News 2: Biotech company announces breakthrough in cancer researchA leading biotech company has announced a major breakthrough in cancer research. The company's new treatment has shown significant efficacy in treating a variety of cancers, offering hope to patients who previously had limited treatment options. This development marks a significant step forward in the fight against cancer.##News 3: Pharma company reports positive results in COVID-19 vaccine trialsA pharmaceutical company has reported positive results in clinical trials for its COVID-19 vaccine candidate. The vaccine has shown high efficacy rates in preventing infection and reducing the severity of symptoms in vaccinated individuals. This news comes as a welcome development in the ongoing battle against the global pandemic.##News 4: Biotech startup secures funding for innovative gene therapyA promising biotech startup has secured funding for its innovative gene therapy approach. The therapy, which targets a range of genetic disorders, has shown promising results in preclinical studies and is now moving towards clinical trials. This funding will help accelerate the development of the therapy and bring it one step closer to market availability.##News 5: Pharma giant announces collaboration with leading research institutionA major pharmaceutical company has announced a collaboration with a leading research institution to advance drug discovery efforts. The partnership aims to leverage the expertise of both organizations to accelerate the development of new treatments for a variety of diseases. This collaboration represents a significant step forward in the quest for innovative therapies.##News 6: Biotech conference showcases latest advancements in gene editing technologyA recent biotech conference showcased the latest advancements in gene editing technology. Researchers presented cutting-edge techniques that have the potential to revolutionize the field of genetic engineering. These advancements hold promise for developing new treatments for a wide range of diseases and disorders.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the world of pharmaceuticals and biotechnology. Thank you for listening!

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Intellia reported an adverse event in its gene therapy trial, causing its stock to drop, adding to existing safety concerns in gene therapy. Analysts downplayed the event, but patient deaths in other trials have raised red flags.## Moderna lost a $760 million bird flu vaccine contract amid uncertainties surrounding its COVID-19 vaccine. ## Other news includes Iteos closing down after a failed trial, Merck and Daiichi Sankyo pulling a lung cancer filing, and Novo opposing pharma tariffs.## AGC Biologics will be at Bio International to discuss their capabilities in drug production. ## Additional stories cover Rocket's gene therapy hold, Biogen's strategy shift, and AbbVie's staff cuts.

This week's episode covers the effectiveness of a fixed-dose albuterol-budesonide combination for asthma, new findings on Nerodomelast for progressive pulmonary fibrosis, the FDA's endorsement of a new COVID-19 vaccine targeting the JN.1 lineage, and insights into extended-phase anticoagulation for pediatric venous thromboembolism.

On this day ... The Golden Gate Bridge opens. This week, as we mark the anniversary of a historic Everest summit, we take a closer look at a new strategy to climb the world's tallest peak. The latest on Russia & Ukraine; Israel & Hamas, and King Charles in Canada. What To Know: What happens next with the spending bill. New recommendation on COVID-19 vaccines. Helpful Links: "All-In" Podcast Everest Climb SUPPORT OUR MISSION: Love nonpartisan news? Want a bigger serving of the serious headlines?  Here's how you can become a SCOOP insider: https://www.scoop.smarthernews.com/get-the-inside-scoop/    Shop our gear!  Instagram: https://www.instagram.com/smarthernews/  Website: https://smarthernews.com/  YouTube Channel: https://www.youtube.com/smarthernews 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.A court has halted the Trump administration's plans to reduce and lay off employees in government agencies, citing a lack of authority. Meanwhile, a report called "Make American Healthy Again" criticizes pharmaceutical lobbying, GLP-1s, and vaccines. The report also addresses rising autism rates and over-medication of children. Bio-Rad is redefining antibody discovery with their Pioneer Antibody Discovery Platform.In other news, Merus' bispecific shows promise in head-and-neck cancer, while Congress narrowly passes a tax bill with changes to IRA penalties and negotiation exemptions for orphan drugs. The FDA vaccine advisors agree on a COVID-19 vaccine as a new framework looms, and GSK wins expansion for Nucala after an FDA delay. Lilly expresses concern as CMS leaves obesity drugs out of Medicare coverage, and Sanofi acquires Vigil for $470 million upfront. And that's all for today's updates in the pharmaceutical and biotech world. Stay tuned for more essential news in our next episode.

A quick update on several controversial new items including a proposed reality show for citizenship, a $400 million plane gift from Qatar to the Pentagon, new FDA recommendations regarding COVID-19 vaccine boosters, and the latest on the "big, beautiful bill."   SUPPORT OUR MISSION: Love nonpartisan news? Want a bigger serving of the serious headlines?  Here's how you can become a SCOOP insider: https://www.scoop.smarthernews.com/get-the-inside-scoop/    Shop our gear!  Instagram: https://www.instagram.com/smarthernews/  Website: https://smarthernews.com/  YouTube Channel: https://www.youtube.com/smarthernews 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Moderna has withdrawn its application for a combination flu and COVID-19 vaccine after discussions with the FDA. The vaccine had shown efficacy in eliciting antibodies, but the company decided to pull the application. In the biotech market, executives from NextGen companies discussed strategies for surviving in what they described as a "moribund" market during a webinar. Biospace's nextgen companies are thriving in a challenging biotech market. Executives discuss survival strategies in the webinar "Are We There Yet?" Pfizer's $6 billion China deal stands out in a competitive market, with Novartis' $4 billion partnership following closely. Biopharma companies are facing pressure to cut assets early due to rising development costs and regulatory hurdles. Lotte Biologics offers specialized end-to-end services at its ADC facility in Syracuse, NY. Other top stories include the FDA's new risk-based approach to COVID-19 vaccines, Genentech's investment in Orionis, and Bio-Rad's new center for excellence for biotherapeutic antibody discovery. Roche's Genentech recently did not win adcomm backing for an expansion. Pfizer has made a deal in China, and RFK claims ignorance about HHS research cuts during a hearing. The top 5 most active corporate VCs in pharma are also highlighted. Additionally, upcoming events and job opportunities in the biotech industry are featured.In conclusion, the biotech market is presenting challenges for companies, but there are opportunities for growth and strategic partnerships. Stay tuned for more updates on regulatory changes, investment deals, and industry trends in the world of Pharma and Biotech. Thank you for listening to Pharma and Biotech daily.

EASY LISTENING DEP'T.: This all starts to sound a little bit like the episode where New England Patriots owner Robert Kraft handed Vladimir Putin one of his Super Bowl rings to show it off, and Putin tucked it in his pocket and declared it a gift. Please visit, read, and support INDIGNITY! https://www.indignity.net/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##FDA Approves New Cancer DrugThe FDA has approved a new cancer drug that has shown promising results in clinical trials. This drug is expected to provide a much-needed treatment option for patients with this type of cancer.##Major Biotech Company Announces MergerA major biotech company has announced a merger with another company in the industry. This merger is expected to create a powerhouse in the biotech world, with the potential for groundbreaking research and development.##COVID-19 Vaccine UpdateThere have been new developments in the race for a COVID-19 vaccine. Several pharmaceutical companies are in the final stages of clinical trials, and there is hope that a vaccine will be available soon.##Drug Pricing Legislation PassesLegislation aimed at addressing drug pricing has passed in Congress. This legislation is expected to lower the cost of prescription drugs for consumers and improve access to affordable medication.##Biotech Startup Receives FundingA promising biotech startup has secured funding to further its research and development efforts. This funding will allow the company to continue its work on innovative therapies and treatments.##FDA Issues Warning About Opioid UseThe FDA has issued a warning about the dangers of opioid use. This warning comes amid a growing opioid crisis in the United States, and highlights the importance of safe prescribing practices.##New Gene Therapy Shows PromiseA new gene therapy has shown promise in treating a rare genetic disorder. This therapy has the potential to revolutionize treatment for patients with this condition, offering hope for improved outcomes.##Pharma Company Launches Patient Assistance ProgramA pharmaceutical company has launched a patient assistance program to help those in need access necessary medications. This program aims to provide support for patients facing financial barriers to treatment.##Biotech Breakthrough in Alzheimer's ResearchA biotech company has made a breakthrough in Alzheimer's research, uncovering new insights into the disease. This discovery could lead to new treatment options for Alzheimer's patients in the future.

What are your thoughts on the measles vaccine debate?I find it troubling that so many vaccines, including COVID-19 and rotavirus, are administered in infancyI suffer greatly with runny nose and phlegm from allergies. Any natural solutions?

Buckle up—this episode is coming in hot! As Pfizer continues its slow release of Covid-19 mRNA vaccine study data, we dig into what's been uncovered so far.Today's guest, Sasha Latypova, a former pharmaceutical industry executive with over 20 years in clinical research and regulatory affairs, shares her findings from the first 400 pages released through a FOIA request. Her analysis raises serious concerns, including whether Pfizer ever conducted proper safety testing and the CDC/FDA's claims that the vaccine “stays in the injection site.” Spoiler: The data suggests otherwise. We're linking the full Pfizer documents on our website so you can see the data for yourself!

What are the downsides of pacemakers? Rethinking low-protein diets for chronic kidney disease; Bright light therapy and creatine alleviate depression; Withdrawal from World Health Organization assailed—but the U.S. can't afford to abdicate to its flawed dietary recommendations; Does a positive ANA blood test necessarily mean you're destined to develop an autoimmune disease? Unprecedented levels of sedative drug abuse among young people calls attention to “Anxious Generation."

The exorbitant cost of new drugs touted for psoriasis in direct-to-consumer ads highlights everything wrong with our medical system; When gastric bypass surgery sends blood sugar out of control; A campaign to ban ultra-processed foods from school meals may help alleviate nutritional threats to kids—but healthy eating begins at home; With winter viruses making the rounds, a remarkable supplement offers potent immune system support. 

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: Pfizer announces positive results from COVID-19 vaccine trialPfizer has announced positive results from its phase 3 trial of a COVID-19 vaccine. The vaccine was found to be over 90% effective in preventing the virus. This is a significant milestone in the fight against the pandemic.##News 2: Moderna's COVID-19 vaccine shows promising resultsModerna has also reported promising results from its COVID-19 vaccine trial. The vaccine was found to be over 94% effective in preventing the virus. This is another positive development in the race to find a safe and effective vaccine.##News 3: Novartis receives FDA approval for new cancer treatmentNovartis has received FDA approval for a new cancer treatment. The treatment is a targeted therapy that has shown promising results in clinical trials. This approval provides new hope for patients with certain types of cancer.##News 4: Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease. The test is designed to detect biomarkers associated with the disease, allowing for earlier diagnosis and treatment. This could have a significant impact on patient outcomes.##News 5: Johnson & Johnson announces breakthrough in HIV vaccine researchJohnson & Johnson has announced a breakthrough in HIV vaccine research. The company has developed a mosaic-based vaccine that has shown promising results in early-stage clinical trials. This could be a major step forward in the fight against HIV.##News 6: AstraZeneca partners with Oxford University on COVID-19 treatmentAstraZeneca has partnered with Oxford University on a potential COVID-19 treatment. The treatment is an antibody cocktail that has shown positive results in early trials. This collaboration could help accelerate the development of much-needed treatments for the virus.##Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates on the latest news and developments in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a significant development in the fight against the pandemic, as it could potentially lead to widespread vaccination and a return to normalcy. ## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received emergency use authorization from the FDA for its COVID-19 vaccine. This is another important step in the fight against the pandemic, as it will allow for the vaccine to be distributed more widely and help to protect more people from the virus. ## Johnson & Johnson applies for emergency use authorization for COVID-19 vaccineJohnson & Johnson has applied for emergency use authorization from the FDA for its COVID-19 vaccine. If approved, this vaccine could provide another option for individuals looking to protect themselves from the virus. ## AstraZeneca faces scrutiny over COVID-19 vaccine dataAstraZeneca is facing scrutiny over the data from its COVID-19 vaccine trials. Questions have been raised about the efficacy of the vaccine, as well as potential safety concerns. This is a reminder of the importance of transparency and thorough evaluation in the development of vaccines. ## Novavax announces positive results for COVID-19 vaccineNovavax has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 85%. This is another promising development in the fight against the pandemic, as it could provide yet another option for vaccination. ## ConclusionIn conclusion, there have been several significant developments in the world of COVID-19 vaccines. From positive results to emergency use authorizations, these updates are a testament to the hard work and dedication of researchers and scientists around the world. As we continue to navigate this challenging time, it is important to stay informed and vigilant in our efforts to combat the pandemic.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: Pfizer announces positive results for new cancer drugPfizer has recently announced positive results from a phase 3 clinical trial for their new cancer drug. The drug showed a significant increase in overall survival rates compared to standard treatments. This is great news for patients with this type of cancer and could potentially lead to a new treatment option in the near future.##News 2: FDA approves new gene therapy for rare genetic disorderThe FDA has approved a new gene therapy for a rare genetic disorder that affects children. This therapy has shown promising results in clinical trials, with patients experiencing significant improvements in their symptoms. This approval marks a major milestone in the field of gene therapy and provides hope for patients with rare genetic disorders.##News 3: Biogen announces breakthrough Alzheimer's drugBiogen has announced a breakthrough in the treatment of Alzheimer's disease with their new drug. The drug has shown to significantly slow the progression of the disease in clinical trials, offering hope to millions of patients and their families. This development could potentially change the landscape of Alzheimer's treatment moving forward.##News 4: Moderna ramps up production of COVID-19 vaccineModerna has announced plans to ramp up production of their COVID-19 vaccine in order to meet global demand. The company has already distributed millions of doses worldwide, with plans to increase production even further in the coming months. This is a positive step towards achieving widespread vaccination and controlling the spread of the virus.##News 5: Novartis partners with research institute on new drug discoveryNovartis has entered into a partnership with a leading research institute to collaborate on new drug discovery efforts. This collaboration brings together expertise from both organizations to accelerate the development of innovative therapies for patients. The partnership highlights the importance of collaboration in driving scientific advancements in the pharmaceutical industry.

While we may associate Messenger RNA (mRNA for short) with the COVID-19 pandemic vaccination programme, its study in fact began over 60 years ago.Born in 1955 in rural Hungary, Katalin Karikó battled critics and scepticism for her research into mRNA for over 30 years before its role in the COVID-19 vaccination programme gained her recognition and, in 2023, a Nobel Prize in Physiology or Medicine. In this interview, Karikó tells us about this journey and why she loves biochemistry, what it's like to win a Nobel Prize, and how she would advise young scientists today. Read Katalin's book: Breaking Through: My Life in Science Read more in Research OutreachImage credit for Thumbnail : OrionNimrod on Wikimedia commons

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New FDA Approval for Cancer TreatmentThe FDA has recently approved a new drug for the treatment of advanced ovarian cancer. This drug has shown promising results in clinical trials, with patients experiencing longer survival rates and fewer side effects compared to traditional treatments. This approval is a significant advancement in the field of oncology and offers hope to patients who are battling this difficult disease.##Breakthrough in Alzheimer's ResearchResearchers have made a breakthrough in the field of Alzheimer's research, identifying a potential new target for treatment. By targeting this specific protein, scientists believe they may be able to slow or even reverse the progression of the disease. This discovery is a major step forward in the fight against Alzheimer's and could potentially change the lives of millions of people worldwide.##Positive Results in COVID-19 Vaccine TrialA leading pharmaceutical company has announced positive results in a phase 3 clinical trial for their COVID-19 vaccine. The vaccine has shown to be highly effective in preventing infection and has been well-tolerated by patients. This news brings hope to many as the world continues to battle the ongoing pandemic, and could potentially lead to widespread vaccination efforts in the near future.##FDA Issues Warning on Popular Diabetes MedicationThe FDA has issued a warning on a popular diabetes medication, citing potential safety concerns. Patients who are currently taking this medication are advised to speak with their healthcare provider about alternative treatment options. This warning serves as a reminder of the importance of monitoring drug safety and efficacy, and highlights the FDA's commitment to protecting public health.##Growing Concerns Over Antibiotic ResistanceHealth officials are increasingly concerned about the rise of antibiotic resistance, which poses a serious threat to public health. Overuse and misuse of antibiotics have led to the development of resistant strains of bacteria, making infections more difficult to treat. It is crucial that healthcare providers and patients alike take steps to combat this growing issue, such as practicing proper antibiotic stewardship and infection control measures.##Innovations in Gene TherapyAdvancements in gene therapy have paved the way for new treatment options for a variety of genetic disorders. By targeting specific genes, scientists are able to correct genetic mutations that cause disease, offering hope to patients who previously had limited treatment options. These innovations have the potential to revolutionize healthcare and improve outcomes for individuals living with genetic conditions.##Rise in Telemedicine UsageThe COVID-19 pandemic has led to a significant rise in telemedicine usage, as patients seek alternative ways to receive medical care while minimizing potential exposure to the virus. Telemedicine offers a convenient and accessible option for patients to consult with healthcare providers, leading to improved access to care and increased patient satisfaction. This trend is likely to continue even after the pandemic subsides, shaping the future of healthcare delivery.##Investments in Biotech StartupsInvestors are increasingly turning their attention towards biotech startups, recognizing the potential for innovation and growth in this sector. These startups are developing cutting-edge technologies and treatments that have the potential to revolutionize healthcare. The influx of investment capital is fueling research and development efforts, bringing new therapies to market at an accelerated pace. This trend highlights the importance of supporting early-stage biotech companies in driving progress within the industry.##

Discover the fascinating history of vaccines in this episode of History Ignited!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer ResearchIn a groundbreaking study published in Nature Medicine, researchers have identified a new potential target for cancer therapy. This discovery could lead to more effective treatments for a wide range of cancers, offering hope to patients around the world.## COVID-19 Vaccine UpdateThe latest data on COVID-19 vaccine effectiveness shows promising results. Several vaccines have been shown to provide high levels of protection against the virus, with some offering more than 90% efficacy. This news brings us one step closer to ending the pandemic.## Drug Approval AnnouncementThe FDA has approved a new drug for the treatment of a rare genetic disorder. This medication has been shown to significantly improve patient outcomes and quality of life. The approval marks a major milestone in the fight against rare diseases.## Biotech Startup Success StoryA small biotech startup has made waves in the industry with their innovative approach to drug development. Their recent success in securing funding and partnerships has put them on the map as a key player to watch in the coming years. ## Pharma Company MergerTwo major pharmaceutical companies have announced plans to merge, creating a powerhouse in the industry. The merger is expected to result in increased resources for research and development, leading to the development of new and improved treatments for patients worldwide.## Clinical Trial ResultsExciting results from a phase III clinical trial show promising outcomes for a new treatment for Alzheimer's disease. The drug has been found to significantly slow the progression of the disease, offering hope to millions of patients and their families.## Regulatory Approval UpdateA new drug seeking regulatory approval has passed a major milestone in the approval process. The FDA has granted priority review status to the medication, which could expedite its availability to patients in need. This news is a significant step forward in bringing this potentially life-saving treatment to market.That's all for today's episode. Stay tuned for more updates on the latest news in Pharma and Biotech. Thank you for listening.

What COVID variant are we on? How dangerous is the new COVID variant? Where does listeria come from? What deli meats have listeria? Is measles still around? Our guest is American Medical Association's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. AMA CXO Todd Unger hosts.

What is the newest COVID vaccine called? When is the new COVID vaccine available? Which COVID 19 vaccine is best? What are the CDC COVID guidelines for vaccines? Our guest is Sandra Fryhofer, MD, AMA's liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP's COVID-19 Vaccine Workgroup. American Medical Association CXO Todd Unger hosts.

Dr. Henry Fraimow is an infectious disease physician at Cooper University Hospital in Camden, NJ. Listen to Henry discuss common patient questions about COVID-19, the early months of the pandemic and the challenges of conducting research during the peak of COVID-19.

During the third hour, Mark Cox discussed recent Second Amendment cases, comments allegedly made by Donald Trump about Milwaukee, faith healing claims by Congresswoman Cory Bush, Bryson DeChambeau's golf victory, how the media covers shootings in relation to bump stocks, and a lawsuit against Pfizer regarding their COVID-19 vaccine. Cox interviewed Luis Valdez from Gun Owners of America about the Supreme Court striking down the bump stock ban and potential legislative responses. 

This week's stories include an endoscopic ablation technique targeting ghrelin production showing results for significant weight loss, research that prior immunity to SARS-CoV-2 does not inhibit response to updated COVID-19 vaccines, and a study from the 2024 Heart Rhythm Society Meeting suggesting oral anticoagulant discontinuation after atrial fibrillation catheter ablation may be feasible and safe.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.BioNTech, known for its partnership with Pfizer in developing the first COVID-19 vaccine in the US market, is expecting a return to revenue growth in 2025 after a sales slump of its COVID vaccine affected its bottom line. The company plans to raise prices on the COVID vaccine to maintain revenue while investing in its oncology pipeline for future gains. Meanwhile, Pfizer and Moderna, the other two COVID vaccine giants, are taking different approaches to post-pandemic growth.NeurVati Neurosciences, a blackstone life sciences-backed company, is focusing on later-stage assets to derisk development in neuroscience R&D. Despite recent setbacks in Alzheimer's and ALS drugs, pharma companies are urged to prioritize understanding the patient journey. Pharma companies are also exploring new ways to deliver gene therapies efficiently. Overall, the industry is adapting to evolving trends and challenges to drive innovation and growth in the life sciences field.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.                                                  >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.                                                                                  Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 1. Introduction and Background of Guests   - Introduction to "Ditch the Lab Coat" podcast emphasizing the focus on Covid-19's past, present, and future.   - Background of Dr. Sumon Chakrabarti as an infectious diseases specialist.   - Dr. Chakrabarti's expertise in tropical medicine and his anecdotal experiences with diseases such as neurocysticercosis.2. Vaccine Efficacy and Policies   - Discussing the stability and effectiveness of COVID-19 vaccines for under 70 populations.   - Debates on COVID-19 booster shots for young, healthy individuals.   - Government policies on vaccinations and the comparison to alcohol and cigarettes accessibility.   - The role of vaccine in individual risk reduction versus transmission prevention.   - Comparison of COVID-19 vaccine with traditional vaccines like measles for public health impact.3. Epidemiological Insights and Disease Transmission   - Concepts of fomite transmission and the role of ventilation in transmission reduction.   - Transmission of infectious diseases like tuberculosis in poorly ventilated spaces.   - The use of masks, especially N95 masks, and related confusion.4. Healthcare Workers' Experiences and Emotional Stress   - Dr. Mark's reflections on emotional stress while working in hospitals.   - Sumon Chakrabarti's personal experiences during the pandemic.   - Healthcare providers' emotional reactions and fears.5. Public Health Messaging and Social Impact   - Regrets over early response and messaging advocating for strict isolation.   - Effects of isolation measures on mental health and widening socioeconomic disparities.   - The credibility of public health messaging and the evolving nature of science.6. Social Media and Public Engagement   - Sumon Chakrabarti's use of Twitter before and after Elon Musk's acquisition.   - The experience of online vitriol and engagement strategies with the public.7. Pandemic Reflections and Measures   - Experiences leading up to the declaration of the pandemic.   - Initial pandemic preparations and avoidance of large gatherings.   - The idea of self-sufficient confinement and its health impacts.8. Impact on Healthcare Systems and Services   - The struggle of healthcare systems with ventilator supplies.   - Halting of non-COVID health services and its consequences.   - Prioritization of COVID-19 patients over other health needs.9. Socioeconomic Factors and Policies   - The shift in perspective on the affected population and the impact of lockdowns.   - Downstream impacts of delayed diagnoses and mental health issues among children.   - Policies crafted by individuals not experiencing the same realities.10. Controversies and Community Perspectives    - Dissenting opinions within the medical community regarding lockdowns.    - The tension between public health guidance and individual freedoms. Summary:- Final thoughts on the episode's discussions.- Acknowledgment of the learning curve throughout the pandemic.- Anticipation for further discussions with Sumon Chakrabarti in upcoming episodes.Timestamps:09:49 Reflecting on pandemic experiences and shift in care.11:15 Fears of death due to pandemic impact.14:40 Medical students sent home due to COVID-19.20:04 Ventilation important in preventing spread of respiratory viruses.21:42 TB spread through air, not just close contact.26:51 Message: Be cautious but don't isolate completely.29:30 Ventilator shortage fears during Covid, healthcare impact.31:12 Implicitly shifting healthcare responsibility to the population.36:22 Frustration over policy makers' lack of experience.39:44 First vaccine dose, limited protection against infection.43:27 COVID vaccine blunts severe disease but not transmission.45:34 COVID vaccines less effective due to mutations.49:22 Healthcare workers struggled as resources dwindled.52:25 Criticism of government's pandemic response and hypocrisy.57:15 Analysis of pandemic impact on various aspects.59:57 Changes take time, hope for better response.© 2024 ditchthelabcoat.com - All Rights Reserved 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: New treatment for Alzheimer's diseaseIn a groundbreaking development, researchers have announced a new treatment for Alzheimer's disease. The drug, called ADX-100, has shown promising results in early clinical trials. It works by targeting the underlying causes of the disease, rather than just managing the symptoms. This could be a game-changer for the millions of people affected by Alzheimer's worldwide.##News 2: Breakthrough in cancer researchScientists have made a significant breakthrough in cancer research. A new study has identified a genetic mutation that plays a key role in the development of certain types of cancer. This discovery could lead to more targeted treatments and improved outcomes for patients. It is an exciting development in the fight against cancer.##News 3: COVID-19 vaccine updateIn the latest update on COVID-19 vaccines, researchers have found that the Pfizer-BioNTech and Moderna vaccines provide strong protection against the Delta variant of the virus. This is reassuring news as the Delta variant continues to spread globally. Vaccines remain our best defense against the virus, and these findings further support their efficacy.##News 4: Gene therapy shows promise for rare genetic disorderGene therapy has shown promise in treating a rare genetic disorder known as Duchenne muscular dystrophy. In a recent clinical trial, patients who received the gene therapy experienced significant improvements in muscle strength and function. This is an encouraging development for those living with this debilitating condition.##News 5: Advances in personalized medicineAdvances in personalized medicine are revolutionizing healthcare. Researchers are now able to analyze an individual's genetic makeup to tailor treatments specifically to their needs. This approach has shown great promise in treating conditions such as cancer, where targeted therapies can be more effective and result in fewer side effects.##News 6: New drug for diabetes managementA new drug has been approved for the management of diabetes. This medication, called GlucoControl, helps regulate blood sugar levels and has shown to be effective in controlling the disease. With the number of people with diabetes on the rise, this new treatment option is a welcome addition to the available therapies.##News 7: Advances in gene editing technologyGene editing technology has made significant advancements in recent years. Scientists can now make precise changes to an organism's DNA, opening up possibilities for treating genetic diseases and improving agricultural practices. This technology has the potential to revolutionize various industries and improve human health.##News 8: Promising results in HIV vaccine trialA new HIV vaccine has shown promising results in a recent clinical trial. The vaccine, which uses a novel approach to stimulate the immune system, demonstrated a high level of efficacy in preventing HIV infection. This is a major breakthrough in the search for an effective HIV vaccine and brings hope for the future.##News 9: Artificial intelligence in drug discoveryArtificial intelligence (AI) is transforming the field of drug discovery. Machine learning algorithms can analyze vast amounts of data to identify potential drug candidates more efficiently than traditional methods. This has the potential to accelerate the development of new treatments and improve patient outcomes.##News 10: Progress in regenerative medicineRegenerative medicine holds great promise for treating a wide range of diseases and injuries. Scientists are making significant progress in growing organs and tissues in the lab, as well as developing therapies to stimulate the body's natural healing processes. This field has the potential to revolutionize healthcare in the coming years.That's all for today's episode. Stay tuned

An update on the surge of COVID and other respiratory diseases in the US and across the world. AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH, discusses the JN.1 variant that's driving this surge and explains how it compares to the Omicron surge. Plus, the latest prescription trends in weight-less drugs like Ozempic and whether or not Ozempic and Wegovy have a side effect of suicidal ideation. American Medical Association CXO Todd Unger hosts.

On today's episode of Danforth Dialogues, Dr. Valerie Montgomery Rice sits down with Dr. Albert Bourla, Chairman and CEO of Pfizer. Join us as we unpack the story behind the decision to invest billions in developing the MRNA vaccine for COVID-19. Dr. Bourla sheds light on the challenges faced, from overcoming skepticism about untested technology to rallying a diverse team in the face of a global crisis.In this thought-provoking conversation, we delve into the intricacies of leadership during a pandemic, the critical role of partnerships with organizations like the NIH, and the profound impact on human lives. Dr. Bourla shares firsthand experiences, revealing the behind-the-scenes efforts that led to the successful development of the vaccine. We also explore the broader implications for the future of healthcare, the importance of combating vaccine misinformation, and the commitment to inclusivity in clinical trials and global vaccine distribution.Stay tuned for a deep dive into the lessons learned, the challenges faced, and the visionary outlook on the intersection of science, leadership, and the collective pursuit of a healthier world. CREDITS Theme Music

Myocarditis is the inflammation of the heart wall tissues that can affect the heart's ability to pump blood, and sometimes cause an irregular or pathologically rapid heartbeat.Dr. Sandeep is a general paediatric and fetal cardiologist and is currently the Medical Director of his practice Pediatrix Northwest Congenital HeartCare in Seattle and Tacoma in Washington state U.S.A, who has created a pathway to help paediatricians with the management of children with symptoms of myocarditis after COVID-19 vaccination.Find out more about Pediatrix: www.pediatrix.comRead the original research: pubmed.ncbi.nlm.nih.gov/36285797

Episode 6 - A Conversation With Dr Anthony Fauci on His Career And His Role in the Responses to AIDS and COVID-19. Recorded December 14, 2023 Dr Michael Saag hosts Dr Anthony Fauci on this episode of the Going anti-Viral podcast, discussing Dr Fauci's career journey, his involvement in AIDS research, and his contribution towards managing other viral diseases. The conversation particularly focuses on the initial response to AIDS, the response to the COVID-19 pandemic, the vaccine development process, and the challenges and successes encountered. The podcast also highlights the significant shift in activism around public health crises, contrasting the constructive role of AIDS activists with the destructive anti-science activism faced during COVID-19. 00:02 Introduction and Background00:42 Dr Anthony Fauci's Early Life and Career02:07 Beginning of the AIDS Story02:12 First Encounter with AIDS and Initial Response03:34 The Turning Point in AIDS Research04:16 Building the AIDS Research Team12:04 The Role of Activism in AIDS Research17:06 The Emergence of COVID-1917:55 The Development of the COVID-19 Vaccine25:58 The Challenges of Anti-Science Activism in the COVID-19 Era29:29 The Future of Public Health Communication30:28 Conclusion and Reflections__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 4 - A Deep Dive into Vaccine Development with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH. This special episode was recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, December 2nd, 2023In this special episode of Going anti-Viral, recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, we explore the challenges and progress in developing vaccines for HIV and COVID-19. Dr Saag discusses with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH, about vaccine development for HIV and its associated challenges and how pre-existing knowledge of similar viruses expedited COVID-19 vaccine development. The conversation also touches upon cellular immunity, broadly neutralizing antibodies, and the potential future of HIV vaccine development.00:08 Introduction and Welcome00:44 Interview with Dr Richard Koup01:05 The History of HIV Vaccine Development02:26 The Challenges of HIV Vaccine Development06:33 The Role of Broadly Neutralizing Antibodies in HIV Vaccine Development14:30 The Potential of Cellular Immunity in HIV Vaccine Development16:08 The Miraculous Development of the COVID-19 Vaccine26:37 The Future of HIV Vaccine Development28:13 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

Can a personalized cancer vaccine extend survival in patients with melanoma? Find out about this and more in today's PV Roundup podcast.